AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01021462 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Comparator: graded infusion of intravenous glucose
Description: A stepwise graded infusion of glucose (20% dextrose \[D20\]) with a stable rate of infusion maintained for 40 minutes for each of 5 steps, with steps at 2,4,6,8 and 12mg/kg/min. Procedure will be identical in Period 1 and Period 2.
Study NCT01853813 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bevacizumab and FOLFIRI
Description: The CENTRAL trial is a biologically enriched prospective phase II clinical trial in which patients treated with first-line modified FOLFIRI and bevacizumab will be prospectively stratified according to LDH serum levels.~After written informed consent patients will be enrolled. Patients will be considered evaluable for study aim if response rate was radiologically evaluated at least once during treatment course.~Treatment will be administered until progression, patients' withdrawal of consent, unacceptable toxicity
Study NCT03747523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ergocalciferol
Description: Investigational drug will be administered to eligible participants in a single dose of 200,000 USP units vitamin D
Study NCT00385047 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group A FMP2.1/AS01B
Study NCT00385047 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group B FMP2.1/AS02A
Study NCT00610155 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: BID
Study NCT00610155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Dose 75 mg titrated to 150 mg, bid
Study NCT00610155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol SR
Description: Dose 50mg titrated to 200 mg, bid
Study NCT01964482 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training
Description: Strength training followed by intake of a protein drink
Study NCT03901820 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medication Interaction System of Dr App (SIMDA)
Description: A module for the electronic clinical records allowing detection of the potential drug interactions
Study NCT01609010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: 375 mg/m2 rituximab i.v. weekly for 4 weeks
Study NCT01609010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/m2 rituximab i.v. weekly for 4 weeks
Study NCT01609010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: interferon-a-2a
Description: 3 MIU/day interferon-a2a s.c. during Week 1, and 4.5 MIU/day s.c. 6 days per week during Weeks 2 through 5
Study NCT04849468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Declofenac
Description: evaluating the preemptive effect of intramuscular declofenac on postoperative analgesia in patients undergoing perianal surgeries under saddle block
Study NCT04849468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saline
Description: evaluating the preemptive effect of intramuscular saline on postoperative analgesia in patients undergoing perianal surgeries under saddle block as control
Study NCT03192306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Merlin
Description: glycolic acid/ethanol solution
Study NCT03192306 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ethanol
Description: Ethanol solution
Study NCT01152749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Single-dose of new NRT product
Study NCT01152749 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Gum
Description: Single-dose of marketed nicotine gum
Study NCT01532518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nepadutant
Description: Nepadutant oral solution
Study NCT02283268 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant von Willebrand Factor (rVWF)
Description: rVWF will be administered by intravenous bolus infusion. Participants planned for major surgery will undergo a baseline pharmacokinetic assessment prior to surgery. The peri- and postoperative substitution regimen will be individualized according to the PK results, intensity and duration of the hemostatic challenge, and the institution´s standard of care.
Study NCT02041663 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNP
Description: Repeated brain natriuretic peptide dosages and cardiac echographies up to day 5
Study NCT00745342 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Teamwork Intervention
Description: Families in the teamwork group received quarterly psychoeducational interventions at regular clinic visits, focusing on promoting family teamwork and reducing diabetes-specific family conflict and diabetes burnout.
Study NCT02892773 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Incentive Spirometry
Description: A respiratory therapist will provide instruction on Incentive Spirometry (I.S.) procedure performance before supervised therapy and monitoring begins.~* Study participants will be asked to take 10 deep breaths through the I.S.'s mouthpiece, followed by a 60 second pause.~* The 10-breath cycle will be repeated 3 times per therapy session.~* Each I.S. therapy session will last about 15 minutes, 3 times per day.~* Lung monitoring and deep breathing measurements will occur during a scheduled I.S. sessions on day 1, 3, and 5 after surgery.
Study NCT02892773 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EzPAP® Positive Airway Pressure
Description: A respiratory therapist will provide instruction on EzPAP® procedure performance before supervised therapy and monitoring begins.~* Study participants will be asked to breathe normally through the EzPAP® device's mouthpiece for 10 breaths, followed by a 60 second pause.~* The 10-breath cycle will be repeated 3 times.~* Each EzPAP® therapy sessions will last about 15 minutes, 3 times per day.~* Lung monitoring will occur during a scheduled EzPAP® sessions on day 1, 3, and 5 after surgery.
Study NCT03084120 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Collection of bloods samples for the mother
Description: -During pregnancy, childbirth and after delivery
Study NCT03084120 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Retrieval of umbilical cord blood.
Description: -During childbirth
Study NCT03084120 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Retrieval of placenta.
Description: -During childbirth
Study NCT03084120 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Collection of newborn's and mother's lock of hair.
Description: -During childbirth
Study NCT03084120 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dietetic Patient Outcomes Questionnaires for the mother.
Description: -During pregnancy and after delivery
Study NCT03084120 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Parental questionnaires : ASQ (Ages & Stages questionnaires) and CFQ (Child Feeding Questionnaire).
Description: -At 2 years of age
Study NCT02682693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab 120 mg every 4 weeks for 6 cycles
Study NCT02682693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: nab-paclitaxel 125 mg/m² weekly for 12 weeks or at day 1,8 q22 for 4 cycles (12 weeks)
Study NCT02682693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin 90 mg/m² every 2 or 3 weeks for 4 times
Study NCT02682693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 600 mg/m² every 2 or 3 weeks for 4 times
Study NCT02682693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 2 weekly in parallel to nab-Paclitaxel
Study NCT02682693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab 6 (8) mg/kg every 3 weeks simultaneously to all chemotherapy cycles
Study NCT02682693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab 420 (840) mg every 3 weeks simultaneously to all chemotherapy cycles
Study NCT00921531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Thalidomide is used for adjuvant therapy for TACE~Thalidomide will be given at the dose of 200 mg/day in beginning, with dose escalation of 100 mg/day each week, until to the dosage of 400 mg/day.
Study NCT00921531 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: TACE (5-FU 1.0 g, OXP 150mg, MMC 10 mg, lipiodol 5-30 ml) will be performed every two months (defined as a course) until no radiological evidence of survival of tumor (based on contrast MRI) or 6 courses.
Study NCT00921531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE (5-FU 1.0 g, OXP 150mg, MMC 10 mg, lipiodol 5-30 ml) will be performed every two months (defined as a course) until no radiological evidence of survival of tumor (based on contrast MRI) or 6 courses.
Study NCT04821180 — intervention group
Intervention type: PROCEDURE
Intervention: Three and four-part proximal humeral fractures' treatment
Description: Open Reduction and Internal Fixation with angle stable plate PHILOS versus RSA (Reverse Shoulder Arthroplasty
Study NCT01615406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc MIP 1404
Description: A single dose of 20 ±3 mCi intravenous (IV) injection of 99mTc MIP 1404
Study NCT03023917 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: umbilical cord milking
Description: Infants were placed at or below level of the placenta and about 25cm of the umbilical cord was vigorously milked towards the umbilicus two to three times before clamping the cord. The milking speed was about 25cm/2 seconds
Study NCT04372433 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IO-202
Description: IO-202 as monotherapy
Study NCT03858205 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03858205 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03858205 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Receive low-dose radiation therapy
Study NCT02300220 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: 500 mg, twice daily for 1 week (oral)
Study NCT02300220 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule, twice daily for 1 week
Study NCT04372433 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IO-202 and Azacitidine
Description: IO-202 and azacitidine combination therapy
Study NCT01302119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2690 Topical Solution, 5%
Description: AN2690 Topical Solution, 5%, applied once daily for 48 weeks
Study NCT01302119 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Solution Vehicle
Description: AN2690 Topical Solution, Vehicle, applied once daily for 48 weeks
Study NCT01055769 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Linezolid
Description: 1. Linezolid OS 600 MG~2. Linezolid Tablet 600 MG
Study NCT01055769 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Linezolid
Description: 1. Linezolid Tablet 600 MG~2. Linezolid OS 600 MG
Study NCT04372433 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IO-202 and Azacitidine + Venetoclax
Description: IO-202 and azacitidine + venetoclax combination therapy
Study NCT02186808 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Procera® Bridge Zirconia
Description: Patients planned for treatment with a tooth-supported 3 to 4-unit bridge in any position of the maxilla or the mandible.
Study NCT00047879 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: PEG-interferon alfa-2b
Description: 0.3 µg/kg of IFN alfa-2b (PEG-Intron once weekly) plus daily oral thalidomide, subcutaneous injection
Study NCT03023917 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: umbilical cord clamping immediately
Description: umbilical cord was cut immediately after birth
Study NCT01873404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG00010
Description: As specified in the treatment arm
Study NCT01873404 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: As specified in the treatment arm
Study NCT03371862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide Pen Injector [Victoza]
Description: Pilot study of liraglutide in patients with short bowel.
Study NCT00047879 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Thalidomide
Description: Two 50mg tablets (100 mg total dose) every night before bedtime starting on day one.
Study NCT01767246 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PFS Algorithm treatment
Description: Physical Therapy treatment for Patellofemoral Syndrome based upon a treatment algorithm. that addresses patients: fear avoidance beliefs, flexibility, body mechanics, and strength. The exercises and treatments are individualized to each patients with the goal of have low fear avoidance beliefs, flexibility, body mechanics, and strength.
Study NCT02207647 — intervention group
Intervention type: OTHER
Intervention: no intervention
Study NCT01767246 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multimodal treatment
Description: Physical Therapy treatment for Patellofemoral Syndrome based upon the Multimodal treatment (Lowry, 2008).
Study NCT03036033 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SaeboGlove
Description: All participants are given a Saebo glove to use during their stroke recovery.
Study NCT02758366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Study NCT02702206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroids
Description: under US guidance, 2ml triamcinolone (1ml/10mg), 0.5ml distilled water and 1ml 1% lidocaine
Study NCT02348788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine + Primaquine
Study NCT02348788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine + Primaquine
Study NCT00612274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Tacrolimus will be administered at a dose of .02mg/kg/d IVCI beginning day -3 until able to take oral medicines reliably. Blood levels will be maintained at 5-10 ng/ml. The oral dose will be 4 times the IV dose. Tacrolimus will be converted to oral dosing prior to hospital discharge. Tacrolimus will be continued until 4 months post transplant (day +120) unless toxicity, refractory GVHD or the development of disease recurrence mandate discontinuation of the drug.
Study NCT00612274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus will be administered as a 12 mg oral loading dose on day -3 followed by 4mg daily. Sirolimus levels will be obtained on day +0 and then at least twice weekly to maintain a trough serum level of 3-12 ng/ml. Sirolimus will be continued until 5 months post transplant (day +150) unless toxicity, refractory GVHD or the development of disease recurrence mandate discontinuation of the drug.
Study NCT00612274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate, dose #1 will be administered on day +1 post transplantation, as an IV bolus, provided at least 24 hours have elapsed following infusion of donor stem cells at a dose of 10mg/m2. Dose #2 of Methotrexate will be administered 48 hours later, as IV bolus on day +3 at a dose of 5mg/m2.
Study NCT01785238 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: renal echography
Description: renal echography to analyse the kidney
Study NCT00643474 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accu-Chek Aviva Meter
Description: 4-point daily glucose monitoring profile 3 times per week
Study NCT00643474 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accu-Chek Aviva Meter
Description: Frequency and timing of SMBG not specified
Study NCT04143854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBA-P01(Botulinum toxin A)
Description: Intramuscular injection; Dose varies by group
Study NCT01785238 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: renal echography
Description: renal echography to analyse the kidney
Study NCT01785238 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood sampling to analyse different parameters of renal function
Study NCT01785238 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling
Description: Blood sampling to analyse different parameters of renal function
Study NCT01785238 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: collection of an urine sample
Description: Collection of an urine sample to perform analysis of renal function parameters
Study NCT01785238 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: collection of an urine sample
Description: Collection of an urine sample to perform analysis of renal function parameters
Study NCT02702206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyaluronic acid
Description: under US guidance, 2.5ml HA (ARTZ, 1% sodium hyaluronate solution, 10mg/mL, molecular weight 0.9x106Da) and 1ml 1% lidocaine
Study NCT02702206 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: under US guidance, 2.5ml normal saline (placebo group). 0.5ml distilled water and 1ml 1% lidocaine
Study NCT01768000 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Cognitive Adaptation Training
Description: Family CAT is a 4 month manualised intervention designed to be administered by families independent of clinician support. A self scoring checklist is provided to assess and tailor Family CAT to the individual, along with descriptions of strategies for bathing, dressing, dental hygiene, make-up, toileting, housekeeping/care of living quarters, laundry, grocery shopping, transportation, management of money and consumables, medication management, social skills, communication and telephone use, leisure skills, work skills, and orientation. Family members will watch the DVD to gain insight into how the strategies can be implemented in real world settings. Having identified the areas of need, family members will administer the interventions and evaluate their effectiveness for the individual.
Study NCT01785238 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood pressure measurement
Study NCT01785238 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood pressure measurement
Study NCT02485210 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endodontic treatment
Description: It will be done the endodontic treatment using the photosynamic therapy for decontamination of the root chanel.
Study NCT02485210 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endodontic treatment
Description: It will be done the endodontic treatment using the photosynamic therapy for decontamination of the root chanel.
Study NCT03646253 — intervention group
Intervention type: OTHER
Intervention: Analysis of radiology (standard radiographies, 2D scan sections and 3D reconstructions)
Study NCT01261533 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: foldable capsular vitreous body(FCVB)
Description: FCVB with silicone oil inside is tamponaded into the vitreous cavity
Study NCT04161794 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multimodal
Description: 2 g EPA/DHA as fish oil, repeated dietary counselling and twice weekly 2 x exercises
Study NCT03004690 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PPE Suit A
Description: In this randomized study following good clinical practice guidelines nineteen study volunteers were recruited to wear one of two different types of randomly allocated PPE suits. Suit A has to be used by randomly selected participants to perform four different tests six times at 22°C on one day and four times at 28°C on another day in the local core facility clinical research center.
Study NCT03004690 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PPE Suit B
Description: Suit B has to be used by randomly selected participants to perform four different tests six times at 22°C on one day and four times at 28°C on another day in the local core facility clinical research center.
Study NCT00762671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ebselen
Description: 150 mg BID for 2 weeks
Study NCT04143854 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection; normal saline
Study NCT02254447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan Cilexetil in formulation 1
Description: Round, biconvex white tablets containing Candesartan cilexetil 16 mg for oral administration
Study NCT02254447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan Cilexetil in formulation 2
Description: Round, biconvex white tablets containing Candesartan cilexetil 16 mg for oral administration
Study NCT02254447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATACAND
Description: Round, biconvex pink tablets containing Candesartan cilexetil 16 mg for oral administration
Study NCT02979262 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fathers for Change